Drugmaker Wyeth on Wednesday said it changed the prescribing recommendations for women taking its hormone replacement therapy products to reflect recent findings that raised safety concerns about the medicines and sparked a nationwide debate.
The labels for Premarin, Prempro and Premphase will now recommend that women remain on the therapies for the shortest duration possible given the individual patient’s treatment goals. The drugs should also not be taken to prevent heart disease, and other treatments should be considered to prevent osteoporosis, the labels now state.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!